TY - JOUR
T1 - c-erbB 2 serum level as prognostic factor in hormonally treated advanced breast cancer patients
AU - Zilembo, N.
AU - Mariani, L.
AU - Martinetti, A.
AU - Miceli, R.
AU - Seregni, E.
AU - Bichisao, E.
AU - La Torre, I.
AU - Pozzi, P.
AU - Ferrari, L.
AU - De Candis, D.
AU - Longarini, V. R.
AU - Bajetta, E.
AU - Bombardieri, E.
PY - 2002/8
Y1 - 2002/8
N2 - To investigate whether c-erbB 2 serum levels may be predictive of clinical response, progression-free and overall survival in postmenopausal women with advanced breast cancer hormonally treated, 265 patients enrolled in previous clinical trials were evaluated. C-erbB 2 serum levels were assessed before the start of treatment and in a subgroup of patients also at the first response evaluation. In addition, serum CA 15.3 levels were determined. The role of c-erbB 2 was investigated by means of multiple regression models in which both c-erbB 2 and CA 15.3 values were modelled as continuous variables together with other known prognostic factors. The failure probability tended to be higher in the presence of high c-erbB 2 levels, but the trend was not statistically significant; in contrast, significant results were obtained for progression-free survival (PFS, P <0.00 1) and overall survival (OS, P = 0.014). The within-patient c-erbB 2 variation significantly predicted PFS (P = 0.006) and OS (P = 0.040). It is worth noting that c-erbB 2 and CA 15.3 baseline levels were significantly correlated and that the prognostic effect of c-erbB 2 tended to disappear in the presence of high CA 15.3 levels for PFS and OS.
AB - To investigate whether c-erbB 2 serum levels may be predictive of clinical response, progression-free and overall survival in postmenopausal women with advanced breast cancer hormonally treated, 265 patients enrolled in previous clinical trials were evaluated. C-erbB 2 serum levels were assessed before the start of treatment and in a subgroup of patients also at the first response evaluation. In addition, serum CA 15.3 levels were determined. The role of c-erbB 2 was investigated by means of multiple regression models in which both c-erbB 2 and CA 15.3 values were modelled as continuous variables together with other known prognostic factors. The failure probability tended to be higher in the presence of high c-erbB 2 levels, but the trend was not statistically significant; in contrast, significant results were obtained for progression-free survival (PFS, P <0.00 1) and overall survival (OS, P = 0.014). The within-patient c-erbB 2 variation significantly predicted PFS (P = 0.006) and OS (P = 0.040). It is worth noting that c-erbB 2 and CA 15.3 baseline levels were significantly correlated and that the prognostic effect of c-erbB 2 tended to disappear in the presence of high CA 15.3 levels for PFS and OS.
UR - http://www.scopus.com/inward/record.url?scp=0036700575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036700575&partnerID=8YFLogxK
U2 - 10.1054/brst.2002.0416
DO - 10.1054/brst.2002.0416
M3 - Article
C2 - 14965684
AN - SCOPUS:0036700575
VL - 11
SP - 286
EP - 294
JO - Breast
JF - Breast
SN - 0960-9776
IS - 4
ER -